Form 4: AnaptysBio CFO Sells Shares After Option Exercise

AnaptysBio CFO Dennis Mulroy exercised stock options and sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc., engaged in several transactions on December 16, 2025.
• Exercised employee stock options to acquire 10,000 shares of Common Stock at an exercise price of $20.16 per share.
• Sold 9,365 shares of Common Stock at a weighted average price of $44.6152 per share, with individual sales ranging from $44.07 to $45.05.
• Sold an additional 6,360 shares of Common Stock at a weighted average price of $45.2062 per share, with individual sales ranging from $45.065 to $45.32.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mulroy on April 11, 2025.
• Acquired 1,324 shares under the Company's Employee Stock Purchase Plan (ESPP).
• Following these transactions, Mulroy directly beneficially owns 9,401 shares of Common Stock.
• Mulroy also holds 70,600 remaining vested employee stock options and additional options to purchase up to 339,440 shares of common stock, which vest according to their terms.

Sentiment

Score: 5

Explanation: The transactions involve an executive exercising options and selling shares under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed negatively, the existence of a 10b5-1 plan suggests these are scheduled liquidity events rather than a reaction to new, negative information. The exercise of options also indicates the executive saw value at the exercise price.

Positives

• The CFO exercised employee stock options, indicating a belief in the value of the stock at the exercise price.
• Acquisition of 1,324 shares through the Company's ESPP demonstrates continued participation in employee benefit programs.

Negatives

• A significant sale of common stock by a key executive, totaling 15,725 shares, could be perceived negatively by some investors, although it was conducted under a pre-arranged 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe the insider selling activity, which could lead to questions about management's confidence, though the 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

The filing reports routine insider transactions (option exercise and sales under a 10b5-1 plan) by the CFO. These pre-scheduled sales do not typically signal a change in the company's fundamental outlook or warrant a strong buy/sell recommendation based solely on this filing. The executive still holds a substantial number of options, suggesting continued alignment with shareholder interests. Investors should consider broader company performance and market conditions rather than these specific transactions for investment decisions.

Keywords

AnaptysBio, ANAB, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, CFO, Dennis Mulroy, 10b5-1 Plan, Equity Compensation